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Background: Pancreatic adenocarcinoma is one of the most lethal cancers, yet it remains understudied and poorly
understood. Hyperinsulinemia has been reported to be a risk factor of pancreatic cancer, and the rapid rise of
hyperinsulinemia associated with obesity and type 2 diabetes foreshadows a rise in cancer incidence. However, the
actions of insulin at the various stages of pancreatic cancer progression remain poorly defined.
Methods: Here, we examined the effects of a range of insulin doses on signalling, proliferation and survival in three
human cell models meant to represent three stages in pancreatic cancer progression: primary pancreatic duct cells,
the HPDE immortalized pancreatic ductal cell line, and the PANC1 metastatic pancreatic cancer cell line. Cells were
treated with a range of insulin doses, and their proliferation/viability were tracked via live cell imaging and XTT
assays. Signal transduction was assessed through the AKT and ERK signalling pathways via immunoblotting.
Inhibitors of AKT and ERK signalling were used to determine the relative contribution of these pathways to the
survival of each cell model.
Results: While all three cell types responded to insulin, as indicated by phosphorylation of AKT and ERK, we found
that there were stark differences in insulin-dependent proliferation, cell viability and cell survival among the cell
types. High concentrations of insulin increased PANC1 and HPDE cell number, but did not alter primary duct cell
proliferation in vitro. Cell survival was enhanced by insulin in both primary duct cells and HPDE cells. Moreover, we
found that primary cells were more dependent on AKT signalling, while HPDE cells and PANC1 cells were more
dependent on RAF/ERK signalling.
Conclusions: Our data suggest that excessive insulin signalling may contribute to proliferation and survival in
human immortalized pancreatic ductal cells and metastatic pancreatic cancer cells, but not in normal adult human
pancreatic ductal cells. These data suggest that signalling pathways involved in cell survival may be rewired during
pancreatic cancer progression.
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The incidence of pancreatic cancer is increasing, in
parallel with the obesity and type 2 diabetes epidemics.
Despite intense research efforts, the average 5-year
survival rate for pancreatic cancer remains below 5%,
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epidemiological studies have drawn a positive link
between high levels of insulin and an increased risk of
pancreatic cancer [1,4,5]. Obesity and early stage type
2 diabetes are both associated with elevated insulin
levels, known as basal hyperinsulinemia [6]. Given that
insulin is a powerful mitogen and that its levels likely
vary physiologically within the pancreas [7], it is possible
that sustained increases in local insulin levels within the
pancreas provide increased growth advantages and
pro-survival effects in cells within the pancreas [8]. Ittd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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on different stages of pancreatic cancer progression.
The molecular mechanisms by which hyperinsulinemia
may affect pancreatic cancer progression remain incom-
pletely understood, but several studies have demonstrated
the importance of the RAS-MEK-ERK pathway and the
PI3K-AKT pathway. Over 90% of human pancreatic
adenocarcinoma cases involve the KRASG12D gain-of-
function mutation, and this mutation is sufficient to
lead to pre-cancerous lesions and rare tumours in mouse
models [9]. The KRasG12D mutation leads to constitutive
activation of RAF-MEK-ERK and PI3K-AKT cascades to
drive uncontrolled growth, proliferation and survival of
cancer cells [10]. KRas-driven transformations can be
inhibited by expression of dominant-negative Raf-1, MEK
or ERK, which all lie downstream of Ras [11,12]. It has
been established that Raf-1 can promote the initiation,
transformation and maintenance of neoplastic lesions in
some cancer models [13,14]. Constitutively active AKT
can also transform normal mouse pancreatic duct cells
into malignant pancreatic cancer cells in vivo [15], but
the inability of PI3K-AKT inhibition to affect several
Ras-driven cancers suggests that KRas acts on multiple
pathways in oncogenesis [10,16,17].
In the present study, we examined the effects and
mechanisms of insulin in three in vitro cell models de-
signed to mimic the progression of pancreatic cancer
in vivo. These cell models were: pancreatic ductal cell
cultures, an immortalized human ductal epithelium
cell line (HPDE), and an advanced metatstatic human
pancreatic ductal cancer cell line (PANC1). We found
that high levels of insulin accelerated the proliferation
of immortalized and metatstatic pancreatic ductal cells
but not primary ductal cells. Furthermore, the molecular
signalling mechanisms activated by insulin were distinct
in each model, suggesting that these processes may be
rewired during the progression of pancreatic cancer.
These studies reveal potential mechanisms of insulin-
mediated growth and survival effects and provide a better
understanding in the etiology of hyperinsulinemia-
associated pancreatic cancer.
Methods
Human mixed pancreatic exocrine and ductal cell culture
Primary pancreatic exocrine cells that would normally
be discarded were obtained from the Vancouver General
Hospital (Vancouver, BC) as part of the Human Islet
Transplant Program, from cadaver organ donors who had
previously provided informed consent. Dr. Warnock’s
organ retrieval protocols are approved by the University of
British Columbia Clinical Research Ethics Board. Tissues
were from 7 donors, males and females between the ages
of 32 and 58. Procedures involved in the culturing, dissoci-
ating and sorting of primary mixed exocrine and ductaltissue were adapted from published protocols, with minor
alterations [18,19]. Briefly, human ductal cell culture was
performed as follows. First, unsorted primary cells,
after being dispersed by shaking incubation for 1 hour
and trituration with trypsin, were plated (10 × 106
cells) in T-150 flasks, to allow preferential adhesion
and removal of fibroblasts. Then, fibroblast-depleted
cell suspensions were then seeded in 6-well plates at
cell density of 1.5 × 106 cells per well for further treat-
ments. For immunoblot analysis, dissociated mixed-
pancreatic exocrine-ductal cells were used. For cell
proliferation and cell survival assays, sorted ductal
cells were used (CD90 negative population). Prior to
insulin treatments, cells were cultured in basal media
(CMRL1066, 0.5 mg/L transferrin, 10 mM nicotina-
mide, 5 μg/L sodium selenium, 0.5% BSA, 2 mM glutam-
ine) for 6 hours, then treated with 0.2, 2, 20, 200 nM of
human recombinant insulin (Sigma Aldrich, Missouri,
USA), 5 μM GW5074 (Life Technologies, California,
USA), or 100 nM Akti-1/2 (EMD Biosciences, Darmstadt,
Germany).
HPDE and PANC1 cell culture and treatment
HPDE cells were kindly provided by Dr. Ming Tsao.
HPDE cells between passages 7 to 15 were used, and
were cultured in KSF medium as previously described
[20], but switched to DMEM for the experiments be-
cause KSF medium contains 779.1 ± 87.43 nM insulin as
measured by radioimmunoassay. PANC1 cells (ATCC,
Manassas, USA) were cultured in DMEM as previously
described [21]. For treatments, cells were washed with
PBS and starved in 1 mg/ml glucose DMEM for for
6 hours (HPDE cells), or 24 hours (PANC1 cells).
Thereafter, the cells were treated with insulin, IGF-1,
DMSO, 10 μM GW5074, 10 μM U0126 (Cell Signaling,
USA), 200 nM Akti-1/2 or 1 μM wortmannin (EMD
Biosciences). These concentrations were chosen based
on the literature and were shown to block signalling in
PANC1 cells.
Cell counting and cell survival assays
The number of cells, live-stained with a concentration of
Hoechst-33342 (50 ng/ml) that does not affect viability
[22], was measured over time using ImageXpressMICRO high
content imaging systems (Molecular Devices, Sunnyvale,
California, USA). Images were analyzed with Acuity Xpress
2.0 (Molecular Devices). Cell death was measured by quan-
tifying the percentage of cells incorporating propidium
iodide (Sigma-Aldrich, 0.5 μg/ml) [23-25]. Cell viability,
as indicated by metabolic capacity, was also quantified
using the XTT kit (ATCC). Bromodeoxyuridine (BrdU)
incorporation (Roche, Basel, Switzerland) was also used to
determine proliferation in primary cells as previously de-
scribed [19,26].
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Cells were lysed and subjected to immunoblotting as
previously described [27]. Polyclonal mouse and rabbit
secondary antibodies, monoclonal antibodies for insulin
receptor, ERK1/2, p-ERK1/2(T202/Y204), AKT, p-AKT
(S473), and cleaved caspase 3 were obtained from Cell
Signaling. Mouse monoclonal beta-actin antibody was
obtained from Novus Biologicals (Littleton, Colorado,
USA). Chemiluminescence of the blots was imaged on
films that were subsequently scanned. The density of
individual bands was quantified using the histogram
function of using Adobe Photoshop CS5 after inversion
and auto-contrast functions were applied to the whole
image. Protein levels were expressed as the fold change
relative to control.
Statistical analysis
All data were analyzed by paired sample t-test, or one-
way or two-way ANOVA, followed by post-hoc tests
(Dunnett’s or Bonferroni analysis) with Prism (GraphPad,
La Jolla, California, USA). Results are presented as
mean ± SEM, and are considered significant if the p-value
was less than 0.05.
Results
Baseline abundance of insulin signalling proteins in
human primary pancreatic ductal cells, human HPDE cells
and human PANC1 cells
Pancreatic ductal adenocarcinoma originates in the exo-
crine pancreas and progresses to a highly invasive state.
In the present study, we attempted to model three states
in this progression: normal pancreatic exocrine ductal
cells to represent the baseline, HPDE cells to represent a
proliferative but non-invasive stage [20,28,29], and
PANC1 cells to represent a metastatic stage [30,31]. As a
first step in comparing these cell models, we sought to
analyze the protein levels of insulin receptor β, IGF1R,
AKT and ERK in a small initial pilot western blot study.
Notably, protein abundance of insulin receptors appeared
to be clearly higher in primary ductal cells than in HPDE
or PANC1 cells, even when a fraction of the lysate was
loaded (Figure 1). On the other hand, the IGF1R was most
highly abundant in HPDE cells (Figure 1). The baseline
abundance of downstream signaling proteins, AKT and
ERK, was more similar between the models. The total
amount of AKT protein appeared to be slightly higher
in PANC1 cells. Most cell batches exhibited negligible
baseline phosphorylation of AKT on serine 473 (Figure 1).
The total amount of ERK tended to be slightly higher in
the HPDE cell line, whereas the baseline phosphorylation
status of ERK on T402/Y204 was consistently higher in
PANC1 cells (Figure 1). While none of these results
should be considered quantitative, due to the small nature
of the pilot study and the use of antibodies, they doprovide some context for the subsequent comparisons of
AKT and ERK signaling in response to insulin and IGF1
ligands.
Insulin signaling in primary human exocrine and ductal
pancreas cells
To set a baseline for our in vitro model of pancreatic
cancer progression, we next sought to establish the effects
of insulin on normal human pancreatic exocrine-ductal
cells. Primary pancreatic exocrine-ductal cells were ex-
posed to a range of insulin doses for 5 minutes (acute)
and 24 hours (chronic) and examined for the activation of
AKT and ERK signalling. Rapid rises in the phosphoryl-
ation of ERK-T402/Y204 and AKT-S473 were detected
after acute insulin treatment, most notably with 20 nM
and 200 nM insulin treatment (Figure 2A,B). Chronic in-
sulin treatments led to an increase in AKT phosphoryl-
ation but not ERK (Figure 2C,D). Proliferative effects of
insulin were not observed in sorted primary pancreatic
ductal cells (Figure 2E,F). Higher levels of insulin elicited
protective effects in sorted primary cells (Figure 2G).
Phase contrast microscopy revealed that high doses of in-
sulin altered the granularity, shape, and distribution in of
human primary ductal cells in culture (Figure 2H).
The importance of two of the major insulin signalling
kinases, ERK and AKT, was evaluated by treating
unstimulated cultures with small molecule inhibitors
targeting AKT (Akti-1/2) or RAF1 (GW5074), an up-
stream kinase of ERK. Inhibition of AKT caused a signifi-
cant increase in PI-positive cells, whereas blocking ERK
signalling did not promote cell death (Figure 2I). These
data suggest that AKT signalling is critical for the survival
of human pancreatic ductal cells, while RAF1/ERK signal-
ling is dispensable, under these basal conditions.
Insulin signalling in HPDE cells
HPDE cells are human pancreatic ductal cells that were
immortalized by transfection of E6E7 protein from human
papilloma virus 16 [20,28,29]. Unlike other pancreatic car-
cinoma cell lines, which commonly reveal homozygous
p16 gene deletion, HPDE cells express normal p16 geno-
type [29]. As compared to other pancreatic carcinoma cell
lines, HPDE cells express relatively lower levels of EGFR,
erbB2, TGF-α, HGFR, VEGF and KGF [29]. However, the
response profiles of this cell line to insulin and IGF1 have
not been reported. This human ductal epithelial cell line
has been proposed as an important tool to study pre-
cancer or early stages of pancreatic cancer [20]. Here, we
used them as a model of proliferating, but not yet cancer-
ous, pancreatic cells. Similar to primary pancreatic ductal
cells, HPDE cells displayed responsiveness to insulin, as
seen by AKT and ERK phosphorylation (Figure 3A,B).
In the absence of serum, insulin as low as 2 nM exhib-
ited protective effects on cell survival in HPDE cells
Figure 1 Baseline abundance of insulin signalling proteins in human primary pancreatic ductal cells, human HPDE cells and human
PANC1 cells. Relative expression of Insulin receptor β (InsRβ), IGF1 receptor (IGF1R), phosphorylated AKT at S473 (p-AKT), total AKT (AKT),
phosphorylated ERK (p-ERK), and total ERK (ERK) were examined under basal conditions. From the left to right, there are three biological
independent primary ductal cells samples, four HPDE cells samples and four PANC1 cells samples from different passages. Note the uneven
loading of primary ductal samples as indicated by the actin loading control, which prevents quantitative comparisons. Other than lanes 1 and 2,
every effort was made to load an equal amount of protein into each lane.
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which activates receptors with 75% structural hom-
ology. Activation of both insulin and IGF1 receptors
has been implicated in pancreatic cancer progression
and chemotherapy resistance [32,33]. Interestingly,
HPDE cells were more sensitive to IGF1 than to insulin
(Figure 3A,B), but differences in cell survival effects
were not observed between these two ligands (Figure 3C).
In the absence of serum or exogenous insulin or IGF1, in-
hibition of RAF1 with GW5074 dramatically decreased
HPDE cell viability after only 23 hours (Figure 3D,E). Con-
trary to what was observed in primary human sorted cells,
inhibition of the PI3K-AKT pathway had no effect on
HPDE cell viability (Figure 3D-F). Thus, the RAF1 pathway,
and not the PI3K/AKT pathway, is required for the
maintenance of HPDE cell survival under these basal
conditions.
Insulin signalling in PANC1 cells
The PANC1 cell line was originally isolated from a pan-
creatic adenocarcinoma containing the constitutively
active KRASG12D mutation, a homozygous p16 deletion
and an inactivating p53R273H mutation [30,31]. This cell
line is routinely used to study the late stages of pancreatic
cancer. Acute and chronic treatment of PANC1 cells with
insulin revealed striking differences in the kinetics anddose–response profiles of AKT and ERK phosphorylation.
Several concentrations of insulin tested elicited acute
AKT and ERK phosphorylation in these experiments
(Figure 4A,B). On the other hand, insulin treatment for
24 hours resulted in maximal AKT activation at the 20
nM dose, without further stimulation by 200 nM insulin.
Notably, 24 hours of insulin treatment was only capable of
activating ERK at lower doses (Figure 4C,D). We have pre-
viously found that lower doses of insulin can be more ef-
fective at activating RAF1/ERK and related pathways in
pancreatic endocrine cells [25,26,34-38] and our recent
mathematical model suggests that such low concentra-
tions are present in the human pancreas [7]. Proliferative
and protective effects were only observed at higher insulin
doses (Figure 4E,F). In PANC1 cells treated for 120 hours,
insulin was more effective at promoting cell viability than
IGF1. The increase in proliferation induced by insulin was
confirmed with BrdU incorporation (Figure 4C). No dif-
ferences were observed between insulin and IGF1 on cell
survival (Figure 4H-I). To the best of our knowledge, this
is the first direct comparison of the effects of insulin and
IGF1 in pancreatic cancer cells.
Next, we assessed the requirement for RAF1/ERK ver-
sus PI3K/AKT signalling on the viability of PANC1 cells.
Inhibition of RAF1 significantly increased cell death
(Figure 5A-C) and reduced cell viability (Figure 5D,E) in
Figure 2 Effects of insulin on AKT and ERK phosphorylation and cell viability in primary human pancreatic duct cells. Phosphorylated
AKT and ERK were measured in primary pancreatic exocrine cultures treated with the indicated concentrations of insulin for 5 minutes (A, B) and
24 hours (C, D) (n =3-4) Fold refers to the fold change of sample relative to control at the same time point. (E) Quantification of automated
cell-counting studies employing live-cell imaging of Hoechst-labeled cell cultures over 60 hours. (n =3). (F) Quantification of proliferation by BrdU
staining of treated relative to untreated over 3 days (n =4). (G) Quantification of the average number of dying/dead treated cells, propidium
iodide (PI) labeled, over 60 hours relative to non-treated cells. (n =3). (H) Human exocrine cells were exposed to 0, 0.2, 2, 20, 200 nM insulin for
3 days. Bright-field images are representative of 3 cultures. (I) Effects of inhibition of RAF1/ERK signalling on PI incorporation with 10 μM GW5074
or AKT signalling with 100 nM Akti1/2 on human primary pancreatic exocrine cell viability (n =3). SF denotes serum free. Repeated Measures
ANOVA analyses with Bonferroni’s post-test were performed. *Represents statistical significance of p < 0.05 when compared to DMSO control.
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bility and cell death was also observed after MEK1/2
inhibition by U0126 (Figure 5A,D,E), similar to the
findings in the HPDE cells. AKT inhibition was muchless effective at inducing PANC1 cell death as assessed
by cell counting, PI incorporation, and cleaved caspase
3 levels (Figure 5A-E). These observations indicate that
the RAF1/ERK pathway, and not the PI3K/AKT pathway,
Figure 3 Effects of insulin on AKT and ERK phosphorylation and cell viability in HPDE cells. (A, B) Phosphorylated AKT and ERK were
measured in HPDE cells treated with a range of insulin and IGF-1 concentrations for 5 minutes (n =10, 8). (D-E) Proliferation of HPDE cells was
assessed by XTT assay. Briefly, cells were treated and the activated XTT reagent was added at designated time, and the absorbance of Δ(A475nm
and A660nm) was measured 6 hours post-addition. Insulin or IGF1 was not added in these studies (n =3). (C, F) Quantification of cell death was
assessed by propidium iodide (PI) incorporation in Hoechst-positive cells. Fold refers to the number of PI positive cells in treatment group relative
to control after 23 hours of treatment (n =3). (A-C). Two-tailed paired sample t-tests were performed. (D-E) One-way ANOVA analyses with
Bonferroni post-test were performed.
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PANC1 cell survival under these basal conditions.
Effects of three insulin analogs on PANC1 cells
Some studies, but not all, have reported that individuals
using long-acting insulin analogs have increased risk of
cancer [39]. As an adjunct to our studies on the effects
of insulin in pancreatic cancer cells, we compared native
insulin to a short-acting insulin analogue (Lispro™) and a
long-acting insulin analogue (Glargine™) on the viability
of PANC1 cells. Acute treatment of PANC1 cells with
recombinant insulin, Lispro and Glargine significantly
increased AKT phosphorylation (Figure 6A). No statis-
tical difference in AKT phosphorylation was observed
between the Lispro and native insulin, although our
studies (n = 16) were not powered to detect very subtle
differences. Glargine was found to induce slightly more
AKT phosphorylation in PANC1 cells when compared
to the other insulin analogues. No differences in ERKphosphorylation were observed (data not shown). Not-
withstanding these modest changes in signalling, we
found that recombinant insulin, Lispro and Glargine led
to similar levels of PANC1 cell viability (Figure 6B).
Interestingly, the viability of PANC1 cells was augmented
with low doses of Glargine (Figure 6B). Together, these
data indicate that all forms of insulin tested were capable
of similar effects on PANC1 cell survival and proliferation,
although Glargine exhibited a shift in potency. Caution
should be exercised when extrapolating these in vitro
conditions to the in vivo clinical situation, since high
nanomolar doses of insulin are not physiologically or
pharmacologically relevant.
Discussion
Insulin and IGF1 are growth factors with putative regula-
tory roles in proliferation, survival and cancer progression
[40]. Given that hyperinsulinemia has been identified as an
independent risk factor for pancreatic cancer [1,2,39,41], it
Figure 4 Effects of insulin on AKT and ERK phosphorylation and cell viability in PANC1 cells. Phosphorylated AKT and ERK were measured
in PANC1 cell cultures treated with the indicated concentrations of insulin for 5 minutes (A, B) and 24 hours (C, D) (n =7-12). (E, F) PANC1
cellular viability was also assessed by XTT at 24 hours or 5 days of incubation, and expressed as fold change in mean absorbance treatment
relative to control (n =5-6). Insulin was not added in these studies (G) PANC1 cell proliferation measured after 24 hours using BrdU (n =6) Insulin
was not added. (H) PANC1 cell death measured by propidium iodide incorporation after 48 hours (n =5). Insulin was not added. (I) Cleaved
caspase 3 was measured after 24 hours (n =5). (A-F, H-I) Two-tail paired sample t-test were performed. *Represents statistical significance of
p < 0.05 when compared to control (0 nM Insulin). # in Figure 4F denotes statistical significance between 200 nM IGF1 and 200 nM insulin when
two-tailed paired sample t-test was performed.
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ling may promote cancer progression. To date, not much
is known about the action of insulin on normal human
pancreatic exocrine and ductal cells. Furthermore, direct
comparisons of insulin signalling effects across models
of different stages of pancreatic cancer have not beenreported. In the present study, we demonstrated that
pancreatic cancer progression is associated with changes
in insulin signalling pathways that underlie cell survival,
proliferation and viability. We found that primary human
ductal cells are responsive to insulin and exhibit re-
duced cell viability when AKT signalling is disrupted.
Figure 5 RAF1/ERK signalling is preferentially required for PANC1 cell survival in the absence of exogenous insulin. (A) Effects of
different small molecule inhibitors on propidium iodide (PI) incorporation (PI) in PANC1 cells were tracked and expressed as the fold change in the
percent of PI and Hoechst co-positive cells over total Hoechst positive cells at that hour relative to t =0 hour. Kinetic data were analyzed relative to
serum-free control by two-way ANOVA (n =3) Data points that have been shaded solid black represent statistical significance when compared to
non-treated conditions at that time point. # Indicates statistical significance in cells treated with Akti1/2 when compared to control at that time point.
(B) Average number of PI positive cells over time of each treated group in Figure 5A is shown as a histogram expressed in arbitrary units (AU).
GW5074 exhibited statistical significance, where as other treatments did not yield significance. U0126 p = 0.38, GW5074 *p = 0.0005, Akti-1/2 p = 0.395,
Wort. p = 0.292 (n = 3). (C) The effect of 24 hours treatment with inhibitors on cleaved caspase 3 protein levels in PANC1 cells. This is a representative
immunoblot of three independent biological replicates (n =3). (D-E) PANC1 cells were serum starved and treated with either DMSO, 10 μM GW5074,
10 μM U0126, 200 nM Akti-1/2 and 1 mM wortmannin (wort.) for 24 hours and 120 hours (n =4-5). Cell viability of PANC1 cells was expressed as the
fold change of the treated relative to control. (C-E) One-way ANOVA analysis with Bonferroni post-test was performed. *Represents statistical
significance of p < 0.05 where treated groups are compared to control (−) in the post-hoc test.
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to insulin, but less so than to IGF1, perhaps due to an
abundance of IGF1 receptors. In contrast to the primary
cells, HPDE cells required MAPK signaling and not AKTsignaling to survive. The metastatic PANC1 cell model
responded to insulin, more so than to IGF1, and also had
a strong dependence on MAPK signalling and not AKT
signalling. Collectively, our results imply a re-wiring of
Figure 6 Effects of insulin analogues on PANC1 cell viability. (A) Effects of recombinant insulin, insulin Lispro, and insulin Glargine on AKT
phosphorylation after 60 minutes (n =16). Two-tailed paired sample t-test revealed insulin Glargine promoted greater stimulation of AKT
phosphorylation than recombinant insulin at the 200 nM insulin concentration denoted by # ( p < 0.05). (B) Cell viability assessed by XTT
assay on PANC1 cells treated with insulin analogues for 24 hours (n =8). Two-tailed t-test were performed, and * denotes statistical significance
when compared to non-treated condition.
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cell survival. Further understanding of how cells favor one
pathway over another in pancreatic cancer progression
may lead to novel approaches to halt early carcinogenesis
and improve the long-term survival of pancreatic cancer
patients.
In the present study, we found that these cell models
derived from exocrine tissue required higher doses of
insulin to elicit responses when compared to our previous
experience with pancreatic exocrine cells that respond to
physiological insulin doses in the high picomolar range
[6,26,34,35,37,38,42]. This finding suggests the possibility
that the exocrine cells and their cancerous descendants
may be somewhat refractory to low concentrations insulin
and may require sustained hyperinsulinemia to accelerate
cancer progression. Multiple epidemiological studies have
demonstrated that the hyperinsulinemic states of obesity
and recent onset type 2 diabetes are associated with differ-
ent types of cancer [43,44], and this has been replicated in
some animal models. For example, elevated insulin levels
have been implicated in in vivo mouse models of breast
cancer [45,46]. The metabolic changes that result from
both conditions make it difficult to discern causal factors
that promote carcinogenesis. Hyperinsulinemia can pre-
cede and lead to the development of obesity [6], which
suggests that it may contribute to carcinogenesis indirectly
as well. Indeed, high levels of circulating insulin have been
associated with increased risk of breast cancer in post-
menopausal women [47,48]. Given the association be-
tween hyperinsulinemia and pancreatic cancer [1], it
has been suggested that excessive secretion of insulin by
pancreatic β-cells required to maintain glucose homeostasis
may directly influence pancreatic carcinogenesis in at-risk
individuals.The mitogenic actions of insulin have been well de-
scribed in vitro and in vivo [49], but little is known of
insulin’s proliferative effects on the endocrine and exo-
crine compartments of the pancreas. We previously
demonstrated that insulin, even at physiological pico-
molar doses [7], promotes the proliferation of pancre-
atic endocrine β-cells [26], but whether similar effects
occur on the exocrine compartment was not known. In
the present study, we did not observe any proliferative
effects of insulin in primary ductal cells or transformed
HPDE cells. Instead, we found that insulin and closely
related IGF1 promoted cell viability and survival in
multiple models of pancreatic cancer progression. Collect-
ively, these findings suggest that the oncogenic properties
of insulin may be due to its effects on survival as opposed
to its mitogenic effects. The downstream mechanisms of
insulin action in these three models remain unclear. How-
ever, a recent report has suggested that HPDE prolifera-
tion depends on Pdx1 [50], which we have shown is an
anti-apoptotic transcription factor controlled by low doses
of insulin [42,51]. Additional studies are warranted to fully
elucidate the mechanisms.
Conclusions
The aim of the present study was to determine whether
the response to insulin was different between primary
human pancreatic ductal cells, an immortalized pancre-
atic ductal cell line (HPDE), and an advanced pancreatic
cancer cell line (PANC1). Indeed, we uncovered some
interesting differences, which may hold clues to the role
of insulin and insulin signalling at different cancer
stages. Our data support a working model (Figure 7)
whereby primary pancreatic duct cells respond to insu-
lin (mostly via AKT signalling), but do not respond with
Figure 7 Working model of insulin’s effects at different stages of pancreatic cancer. Our data support a model whereby primary pancreatic
duct cells respond to insulin (mostly via AKT signalling), but do not increase proliferation or survival. On the other hand, proliferative and
cancerous pancreatic ductal cells respond via both AKT and ERK signalling, with cell survival predominantly controlled by the ERK pathway.
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proliferative and cancerous pancreatic ductal cells respond
via both AKT and ERK signalling, with the ERK pathway
being the predominant pathway controlling survival. The
role of insulin during cancer progression has been debated
[52-54]. The present study examined the actions of insulin
on cell viability across different stages of pancreatic cancer
in vitro. If the cell models chosen in this study faithfully
recapitulate the natural progression of the disease, our ex-
perimental data may suggest that hyperinsulinemia may
not play a role in initiating pancreatic cancer, but high
levels of insulin may accelerate the cancer progression via
increased RAF1/ERK-dependent cell survival. The studies
described in this manuscript have the caveats of employ-
ing only a single cell line to represent dividing duct and
adenocarcinomas and of being entirely in vitro. Comple-
mentary in vivo studies are urgently needed to assess the
role of insulin and insulin signalling on pancreatic cancer
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